Compare · NVS vs TLPH
NVS vs TLPH
Side-by-side comparison of Novartis AG (NVS) and Talphera Inc. (TLPH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVS and TLPH operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $286.91B, about 3934.6x TLPH ($72.9M).
- Over the past year, NVS is up 24.2% and TLPH is up 199.4% - TLPH leads by 175.3 points.
- TLPH has been more active in the news (8 items in the past 4 weeks vs 1 for NVS).
- NVS has more recent analyst coverage (25 ratings vs 2 for TLPH).
- Company
- Novartis AG
- Talphera Inc.
- Price
- $150.34-1.97%
- $1.41+0.00%
- Market cap
- $286.91B
- $72.9M
- 1M return
- -2.34%
- +71.01%
- 1Y return
- +24.17%
- +199.45%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2011
- News (4w)
- 1
- 8
- Recent ratings
- 25
- 2
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Latest NVS
- The Quest to Repair What Multiple Sclerosis Takes Away
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- Novartis AG upgraded by Argus with a new price target
- Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
- SEC Form S-8 filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form IRANNOTICE filed by Novartis AG
Latest TLPH
- Director Wan Mark A was granted 5,100 shares, increasing direct ownership by 58% to 13,959 units (SEC Form 4)
- Director Todisco Joseph was granted 5,100 shares, increasing direct ownership by 80% to 11,497 units (SEC Form 4)
- Director Jain Abhinav was granted 5,100 shares, increasing direct ownership by 70% to 12,412 units (SEC Form 4)
- Director Hoffman Stephen J was granted 5,100 shares, increasing direct ownership by 58% to 13,959 units (SEC Form 4)
- Director Broadfoot Jill Marie was granted 5,100 shares, increasing direct ownership by 60% to 13,647 units (SEC Form 4)
- Director Bozilenko Marina was granted 5,100 shares, increasing direct ownership by 56% to 14,147 units (SEC Form 4)
- Director Adams Adrian was granted 5,100 shares, increasing direct ownership by 29% to 22,709 units (SEC Form 4)
- Talphera Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- H.C. Wainwright resumed coverage on Talphera with a new price target
- Chief Medical Officer Aslam Shakil covered exercise/tax liability with 4,518 shares, decreasing direct ownership by 6% to 76,542 units (SEC Form 4) to cover taxes